Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register
- PMID: 26368360
- DOI: 10.1111/jth.13142
Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register
Abstract
Introduction: von Willebrand factor (VWF) plays a critical role in platelet adhesion and aggregation after vascular injury and at sites of high shear rate. Elevated VWF levels are associated with an increased risk of ischemic cardiovascular events; however, it is unclear whether VWF deficiency is protective against atherosclerosis. We aimed to compare the prevalence of cardiovascular disease (CVD) among patients with and without von Willebrand disease (VWD).
Methods: A cross-sectional analysis was performed on discharge data for adults from the Nationwide Inpatient Sample (NIS) between the years 2009 and 2011. CVD was defined as ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, or peripheral vascular disease. For prevalence calculations and statistical analyses, we used discharge-level weights provided by the NIS to reflect national estimates. CVD was compared across groups by use of the Rao-Scott chi-square test. Multivariable logistic regression was used to estimate the likelihood of CVD in VWD patients after adjustment for age, gender, and CVD-related risk factors.
Results: The prevalence of CVD in VWD patients was less than the prevalence of CVD in non-VWD patients (15.0% versus 26.0%). VWD was associated with a decreased likelihood of CVD after adjustment for age, gender, and CVD-related risk factors (odds ratio 0.85; 95% confidence interval 0.79-0.92).
Discussion: These findings indicate that the risk of CVD is decreased among VWD patients, and that VWF deficiency may be protective against CVD.
Keywords: cardiovascular disease; thrombosis; von Willebrand disease; von Willebrand factor; von Willebrand factor deficiency.
© 2015 International Society on Thrombosis and Haemostasis.
Comment in
-
The good and the bad.J Thromb Haemost. 2015 Nov;13(11):1947. doi: 10.1111/jth.13161. Epub 2015 Oct 19. J Thromb Haemost. 2015. PMID: 26478183 No abstract available.
Similar articles
-
The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease.Tex Heart Inst J. 2022 Jul 1;49(4):e207402. doi: 10.14503/THIJ-20-7402. Tex Heart Inst J. 2022. PMID: 35819472 Free PMC article.
-
Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease.Clin Appl Thromb Hemost. 2018 Jan;24(1):93-99. doi: 10.1177/1076029616670258. Epub 2016 Sep 21. Clin Appl Thromb Hemost. 2018. PMID: 27655998 Free PMC article. Clinical Trial.
-
Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels.J Thromb Haemost. 2015 Feb;13(2):228-36. doi: 10.1111/jth.12799. Epub 2015 Jan 9. J Thromb Haemost. 2015. PMID: 25425019
-
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. doi: 10.1177/1076029606291401. Clin Appl Thromb Hemost. 2006. PMID: 16959681 Review.
-
Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570. Blood Coagul Fibrinolysis. 2009. PMID: 19786936 Review.
Cited by
-
Von Willebrand Factor Collagen-Binding Activity and Von Willebrand Factor-Mediated Platelet Adhesion in Patients with Coronary Artery Disease.Biomedicines. 2024 Sep 3;12(9):2007. doi: 10.3390/biomedicines12092007. Biomedicines. 2024. PMID: 39335520 Free PMC article.
-
Von Willebrand Disease Epidemiology, Burden of Illness and Management: A Systematic Review.J Blood Med. 2023 Mar 2;14:189-208. doi: 10.2147/JBM.S389241. eCollection 2023. J Blood Med. 2023. PMID: 36891166 Free PMC article. Review.
-
Von Willebrand Disease in Older Patients: A Retrospective Electronic Health Record Review.Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221146740. doi: 10.1177/10760296221146740. Clin Appl Thromb Hemost. 2022. PMID: 36536550 Free PMC article.
-
Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects.Front Cardiovasc Med. 2022 Dec 2;9:1038030. doi: 10.3389/fcvm.2022.1038030. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36531725 Free PMC article. Review.
-
Lower levels of vWF are associated with lower risk of cardiovascular disease.Res Pract Thromb Haemost. 2022 Nov 6;6(7):e12797. doi: 10.1002/rth2.12797. eCollection 2022 Oct. Res Pract Thromb Haemost. 2022. PMID: 36381288 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
